Capmatinib showed a clinically meaningful rate of anti-tumor activity and an acceptable safety profile in pretreated advanced NSCLC patients with either MET gene copy number (GCN) ≥6 and/or METex14 mutation [59]. This evidence concerns the gene MET and non-small cell lung carcinoma.